1. Home
  2. UAMY vs GYRE Comparison

UAMY vs GYRE Comparison

Compare UAMY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

HOLD

Current Price

$5.63

Market Cap

829.0M

Sector

Industrials

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.17

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAMY
GYRE
Founded
1968
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
829.0M
755.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UAMY
GYRE
Price
$5.63
$7.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$5.69
$17.00
AVG Volume (30 Days)
8.5M
91.0K
Earning Date
11-12-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.04
Revenue
$31,857,819.00
$107,265,000.00
Revenue This Year
$159.13
$11.59
Revenue Next Year
$228.42
$26.31
P/E Ratio
N/A
$185.48
Revenue Growth
177.97
2.13
52 Week Low
$1.21
$6.11
52 Week High
$19.71
$14.42

Technical Indicators

Market Signals
Indicator
UAMY
GYRE
Relative Strength Index (RSI) 45.95 38.95
Support Level $4.36 $7.05
Resistance Level $6.91 $7.35
Average True Range (ATR) 0.62 0.33
MACD 0.18 -0.06
Stochastic Oscillator 49.12 13.45

Price Performance

Historical Comparison
UAMY
GYRE

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: